Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 131

Sort by

Sort Order Select

Journal Articles

Clinical Outcomes of Immune-Mediated Thrombotic Thrombocytopenic Purpura from a Multinational Patient Population

Paul Coppo, Flora Peyvandi, Marie Scully, Johanna A. Kremer Hovinga, Ragy Saad, Maria Jose Aragon, Enrico Ferri Grazzi, Ping Du, Loredana Cuccia, Hamid Ferdosi

Blood (2024) 144 (Supplement 1): 5542.

https://doi.org/10.1182/blood-2024-208741

Published: 2024

Journal Articles

Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial

Blood (2024) 143 (22): 2256–2269.

https://doi.org/10.1182/blood.2023021864

Published: 2024

Includes: Supplemental data

Journal Articles

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial

Steven W. Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Kaan Kavakli, Anna Kiialainen, Sonia Deb, Markus Niggli, Tiffany Chang, Michaela Lehle, Karin Fijnvandraat

Blood (2024) 143 (14): 1355–1364.

https://doi.org/10.1182/blood.2023021832

Published: 2024

Includes: Supplemental data

Journal Articles

The Histopathological Landscape of Synovitis in Hemophilic Arthropathy

Roberta Gualtierotti, Chiara Suffritti, Carlo Pescia, Andrea Giachi, Silvia Spena, Federico Molfino, Stanislao Lavorato, Eleonora Semproni, Addolorata Truma, Sara Arcudi, Alessandro Ciavarella, Marco Maggioni, Umberto Gianelli, Simona Maria Siboni, Jacopo Acquati Lozej, Luigi Piero Solimeno, Flora Peyvandi

Blood (2023) 142 (Supplement 1): 5481.

https://doi.org/10.1182/blood-2023-173554

Published: 2023

Journal Articles

Genetic Variants Associated with High Plasma Levels of Factor VIII and Von Willebrand Factor in a Family with Thrombotic Episodes

Silvia Spena, Andrea Cairo, Francesca Gianniello, Emanuela Pappalardo, Mimosa Mortarino, Isabella Garagiola, Ida Martinelli, Flora Peyvandi

Blood (2023) 142 (Supplement 1): 5402.

https://doi.org/10.1182/blood-2023-189383

Published: 2023

Journal Articles

Post-Marketing Observational Study of the Safety and Efficacy of Fibrinogen Concentrate in Congenital Fibrinogen Deficiency in Patients of All Ages

Flora Peyvandi, Gita Pezeshki, Cristina Solomon

Blood (2023) 142 (Supplement 1): 5514.

https://doi.org/10.1182/blood-2023-185849

Published: 2023

Journal Articles

Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)

Blood (2023) 142 (Supplement 1): 2636.

https://doi.org/10.1182/blood-2023-179316

Published: 2023

Journal Articles

Once-Weekly Efanesoctocog Alfa Prophylaxis Provided High Sustained Factor VIII Activity Levels, Independent of Blood Group, in Children <12 Years of Age with Severe Hemophilia A

Flora Peyvandi, Cristina Tarango, Mindy Simpson, Manuela Albisetti, Maria Teresa Álvarez-Roman, Anthony KC Chan, Julie Curtin, Linda Bystrická, Elena Santagostino, Ekaterina Gresko, Sriya Gunawardena, Chandravathi Vage, Nancy Wong

Blood (2023) 142 (Supplement 1): 506.

https://doi.org/10.1182/blood-2023-188649

Published: 2023

Journal Articles

Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study

Steven Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Kaan Kavakli, Anna Kiialainen, Tiffany Chang, Michaela Lehle, Markus Niggli, Karin Fijnvandraat

Blood (2023) 142 (Supplement 1): 505.

https://doi.org/10.1182/blood-2023-177963

Published: 2023

Journal Articles

Estimating the Population-Based Prevalence of Congenital Thrombotic Thrombocytopenic Purpura Using Large-Scale Sequencing Data

Omid Seidizadeh, Andrea Cairo, Ilaria Mancini, Pasquale Agosti, Frits Rosendaal, Flora Peyvandi

Blood (2023) 142 (Supplement 1): 693.

https://doi.org/10.1182/blood-2023-180560

Published: 2023

Journal Articles

Complement activation and renal dysfunction in patients with acquired thrombotic thrombocytopenic purpura

Massimo Cugno, Ilaria Mancini, Dario Consonni, Valentina De Zan, Gianluigi Ardissino, Samantha Griffini, Elena Grovetti, Luigi Porcaro, Barbara Ferrari, Andrea Artoni, Flora Peyvandi

Blood (2023) 141 (18): 2278–2282.

https://doi.org/10.1182/blood.2022018644

Published: 2023

Includes: Supplemental data

Journal Articles

Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study

Lynn Malec, An Van Damme, Anthony K. C. Chan, Mariya Spasova, Nisha Jain, Charlotte Sensinger, Jennifer Dumont, Stefan Lethagen, Manuel Carcao, Flora Peyvandi

Blood (2023) 141 (16): 1982–1989.

https://doi.org/10.1182/blood.2022017780

Published: 2023

Includes: Supplemental data

Journal Articles

Markedly Reduced FVIII Recovery Associated with Anti-FVIII Peg Antibodies after BNT162b2 Sars-Cov-2 Vaccination

Carla Valsecchi, Roberta Gualtierotti, Sara Arcudi, Alessandro Ciavarella, Lucia Schiavone, Cristina Novembrino, Simona Maria Siboni, Pier Mannuccio Mannucci, Flora Peyvandi

Blood (2022) 140 (Supplement 1): 11286–11287.

https://doi.org/10.1182/blood-2022-162183

Published: 2022

Journal Articles

The Role of ADAMTS13 Activity Levels on Disease Exacerbation or Relapse in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the Phase 3 HERCULES and Post-HERCULES Studies

Johanna A. Kremer Hovinga Strebel, Javier de la Rubia, Katerina Pavenski, Ara Metjian, Paul Knoebl, Flora Peyvandi, Spero Cataland, PAUL Coppo, Umer Khan, Laurel A. Menapace, Ana Paula Marques, Sriya Gunawardena, Marie Scully

Blood (2022) 140 (Supplement 1): 5651–5653.

https://doi.org/10.1182/blood-2022-156306

Published: 2022

Journal Articles

Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study

Steven W. Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Anna Kiialainen, Tiffany Chang, Michaela Lehle, Karin Fijnvandraat

Blood (2022) 140 (Supplement 1): 457–459.

https://doi.org/10.1182/blood-2022-157264

Published: 2022

Journal Articles

Liver Health in Patients with Hemophilia: Residual Risk Factors of Liver-Related Complications after HCV Clearance

Vincenzo La Mura, Niccolò Bitto, Cecilia Capelli, Simona Maria Siboni, Sara Arcudi, Alessandro Ciavarella, Roberta Gualtierotti, Flora Peyvandi

Blood (2022) 140 (Supplement 1): 8440–8441.

https://doi.org/10.1182/blood-2022-163087

Published: 2022

Journal Articles

Hemorrhagic and Thrombotic Adverse Events Associated with Emicizumab and Extended Half-Life FVIII Replacement Drugs in Patients with Hemophilia a: Data from the Eudravigilance Database

Maria Abbattista, Alessandro Ciavarella, Declan Noone, Flora Peyvandi

Blood (2022) 140 (Supplement 1): 462–463.

https://doi.org/10.1182/blood-2022-166191

Published: 2022

Journal Articles

A Computer-Aided Diagnosis Tool for the Detection of Hemarthrosis By Remote Joint Ultrasound in Patients with Hemophilia

Roberta Gualtierotti, Sara Arcudi, Alessandro Ciavarella, Marco Colussi, Sergio Mascetti, Claudio Bettini, Flora Peyvandi

Blood (2022) 140 (Supplement 1): 464–465.

https://doi.org/10.1182/blood-2022-163690

Published: 2022

Journal Articles

Assessing Sequence Similarity between FVIII-Derived B-Cell Epitopes and Pathogen-Derived B-Cell Epitopes and the Risk of Inhibitor Development in Patients with Severe Hemophilia a

Shermarke Hassan, Guido Baselli, Roberta Palla, Frits Richard Rosendaal, Flora Peyvandi

Blood (2022) 140 (Supplement 1): 11282–11283.

https://doi.org/10.1182/blood-2022-165136

Published: 2022

Journal Articles

Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results

Frank W. G. Leebeek, Flora Peyvandi, Miguel Escobar, Andreas Tiede, Giancarlo Castaman, Michael Wang, Tung Wynn, Jovanna Baptista, Yi Wang, Jingmei Zhang, Björn Mellgård, Gülden Özen

Blood (2022) 140 (2): 89–98.

https://doi.org/10.1182/blood.2021014810

Published: 2022

Includes: Supplemental data

NARROW

Clinical Outcomes of Immune-Mediated Thrombotic Thrombocytopenic Purpura from a Multinational Patient Population

Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial

The Histopathological Landscape of Synovitis in Hemophilic Arthropathy

Genetic Variants Associated with High Plasma Levels of Factor VIII and Von Willebrand Factor in a Family with Thrombotic Episodes

Post-Marketing Observational Study of the Safety and Efficacy of Fibrinogen Concentrate in Congenital Fibrinogen Deficiency in Patients of All Ages

Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)

Once-Weekly Efanesoctocog Alfa Prophylaxis Provided High Sustained Factor VIII Activity Levels, Independent of Blood Group, in Children <12 Years of Age with Severe Hemophilia A

Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study

Estimating the Population-Based Prevalence of Congenital Thrombotic Thrombocytopenic Purpura Using Large-Scale Sequencing Data

Complement activation and renal dysfunction in patients with acquired thrombotic thrombocytopenic purpura

Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study

Markedly Reduced FVIII Recovery Associated with Anti-FVIII Peg Antibodies after BNT162b2 Sars-Cov-2 Vaccination

The Role of ADAMTS13 Activity Levels on Disease Exacerbation or Relapse in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the Phase 3 HERCULES and Post-HERCULES Studies

Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study

Liver Health in Patients with Hemophilia: Residual Risk Factors of Liver-Related Complications after HCV Clearance

Hemorrhagic and Thrombotic Adverse Events Associated with Emicizumab and Extended Half-Life FVIII Replacement Drugs in Patients with Hemophilia a: Data from the Eudravigilance Database

A Computer-Aided Diagnosis Tool for the Detection of Hemarthrosis By Remote Joint Ultrasound in Patients with Hemophilia

Assessing Sequence Similarity between FVIII-Derived B-Cell Epitopes and Pathogen-Derived B-Cell Epitopes and the Risk of Inhibitor Development in Patients with Severe Hemophilia a

Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only